M-9, r. 12.2.1 - Regulation respecting certain professional activities that may be engaged in by a pharmacist

Full text
3. A pharmacist may also prescribe
(1)  antiviral treatment to a patient showing signs and symptoms similar to herpes zoster, except where they are present in the head region;
(2)  treatment against influenza or coronavirus disease to a symptomatic patient who is at risk of developing complications.
The pharmacist must then enter the reasons for initiating medication therapy on a form to be given to the patient. In addition, the pharmacist must refer the patient to a physician or specialized nurse practitioner:
(1)  within 3 days after the initiation of the antiviral treatment against herpes zoster;
(2)  2 days after the initiation of the treatment against influenza or coronavirus disease, if the condition of the patient deteriorates.
O.C. 1400-2020, s. 3; O.C. 623-2022, s. 1.
3. A pharmacist may also prescribe
(1)  antiviral treatment to a patient showing signs and symptoms similar to herpes zoster, except where they are present in the head region;
(2)  antiviral treatment against influenza to a symptomatic patient who is at risk of developing complications.
The pharmacist must then enter the reasons for initiating medication therapy on a form to be given to the patient. In addition, the pharmacist must refer the patient to a physician or specialized nurse practitioner:
(1)  within 3 days after the initiation of the antiviral treatment against herpes zoster;
(2)  2 days after the initiation of the antiviral treatment against influenza, if the condition of the patient deteriorates.
O.C. 1400-2020, s. 3.
In force: 2021-01-25
3. A pharmacist may also prescribe
(1)  antiviral treatment to a patient showing signs and symptoms similar to herpes zoster, except where they are present in the head region;
(2)  antiviral treatment against influenza to a symptomatic patient who is at risk of developing complications.
The pharmacist must then enter the reasons for initiating medication therapy on a form to be given to the patient. In addition, the pharmacist must refer the patient to a physician or specialized nurse practitioner:
(1)  within 3 days after the initiation of the antiviral treatment against herpes zoster;
(2)  2 days after the initiation of the antiviral treatment against influenza, if the condition of the patient deteriorates.
O.C. 1400-2020, s. 3.